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Abstract
OBJECTIVE: To evaluate the effectiveness and safe-
ty of Chinese herbal medicine (CHM) in the treat-
ment of subacute thyroiditis.
METHODS: Randomized controlled trials found in
PubMed, Cochrane Library, and three Chinese data-
bases were selected. RevMan 5.2 software was
used to analyze the data with relative risk or mean
difference, expressed with 95% of confidence inter-
val. The quality of trials was assessed and graded
the quality of evidence with GRADE profiler soft-
ware.
RESULTS: Twenty one studies were included. CHM
was superior to Western Medicine (include predni-
sone and NSAIDs) in abating fever, relieving thyroid
pain, recovering blood sedimentation, improving
thyroid function, and preventing hypothyroidism
(P<0.05), while no statistical differences were found
in eliminating goiter and reducing relapse rate.
CHM plus Western Medicine were superior to West-
ern Medicine in abating fever, relieving thyroid
pain, eliminating goiter, and reducing relapse rate,
while no statistical differences (P>0.05) were found
in recovering blood sedimentation and improving
thyroid function. The incidence of adverse reac-
tions in treatment group was lower than that in
control group (relative risk was 0.12 and 95% confi-
dence interval was 0.03-0.51). The methodological
quality of trials is generally poor with a high risk of
bias.
CONCLUSION: CHM (particularly CHM combined
with Western Medicine) used to treat subacute thy-
roiditis may improve clinical symptoms and signs,
reduce relapse rate, and alleviate the side effects of
hormones. Due to poor methodological quality of
included trials, further more high-quality studies
are warranted to confirm the effectiveness and safe-
ty of CHM.
© 2014 JTCM. All rights reserved.
Key words: Drugs, Chinese herbal; Thyroiditis, sub-
acute; Randomized controlled trial; Review, system-
atic
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INTRODUCTION
Subacute thyroiditis, also called subacute granuloma-
tous thyroiditis, (pseudo-) giant cell thyroiditis, or de
Quervain's thyroiditis, is caused by viruses with main
symptoms of fever (exceeding 38℃ in most cases), goi-
ter, and thyroid pain.1 It is the most commonly seen
disease with thyroid pain.2 Its incidence, reportedly
4.9-12.1 cases in every 100 000 people, is increasing in
recent years.3,4 The disease mainly affects people aged
30-50 years in a male: female ratio of 1∶3-7.1,4-6 Al-
though subacute thyroiditis is a self-limited disease, pa-
tients have obvious local or systemic symptoms with an
illness course lasting 6-12 months.2 Several months or
years after treatment, its relapse rate is about 20%, and
10%-15% of patients can suffer from permanent hypo-
thyroidism.3,7
Guideline for diagnosing and treating subacute thyroid-
itis is not yet internationally established. Early treat-
ment aims to reduce inflammation and alleviate pain,
and mild cases are treated with acetylsalicylic acid
and non-steroidal anti-inflammatory drugs
(NSAIDs). Moderate or severe cases are given gluco-
corticoid hormone orally.2 Hormones can be used to
rapidly alleviate symptoms but cannot prevent hypo-
thyroidism.3 Because of its side effects, hormones are
used sparingly.
In Traditional Chinese Medicine (TCM), subacute thy-
roiditis is mainly treated by dispelling wind, clearing
away heat, resolving phlegm, and removing mass.8
Some clinical research has found that Chinese herbal
medicine (CHM) alone or combined with Western
Medicine can improve the effectiveness of subacute thy-
roiditis, lower its relapse rate and the incidence of hy-
pothyroidism, and reduce the side effects of hor-
mones.9 This study aims to summarize the randomized
controlled trials (RCTs) on the treatment of subacute
thyroiditis with CHM, evaluate their effectiveness and
safety of as compared with Western Medicine or place-
bo, and provide evidence for clinical treatment.
METHODS
Literature retrieval
China National Knowledge Infrastructure Database
(CNKI), China Science and Technology Journal Data-
base (VIP) for Chinese Technical Periodicals, China Bi-
ological Medicine Database (CBM), PubMed, and Co-
chrane Library (2013, Issue 5) were searched up to
June 2, 2013, regardless of language.
Searched key phrases include subacute thyroiditis, Tra-
ditional Chinese Medicine, Chinese herbal medicine,
combination of CHM with Western Medicine, ran-
domization, and therapy. Methods for retrieval are sum-
marized according to the features of each database in
Table 1.
Inclusion criteria
Types of trials: in RCTs on the treatment of subacute
thyroiditis with CHM, patients randomly divided into
groups were regarded as conforming to inclusion crite-
ria.
Participations: the trials must explicitly report the diag-
nose of subacute thyroiditis, including symptoms,
signs, biochemical examination, and imaging tests.
They must also give the basic data including sex, age,
and patient illness course.
Types of treatment: patients in the treatment group
were treated with CHM regardless of its dosage form
and medication. Patients in the control group were
treated with no treatment, placebo, or Western Medi-
cines, such as NSAIDs and hormones. Patients in the
treatment group were treated with CHMs plus the
same western drugs as in the control group.
Outcome evaluation: according to the guideline for di-
agnosing and treating subacute thyroiditis issued in
China, treatment aims to reduce inflammation and alle-
viate pain. Therefore, the following primary outcome
indexes were included in this review: (a) fever-abating
time; (b) time for abatement of thyroid pain; (c) time
for elimination of goiter; (d) incidence of hypothyroid-
ism; and (e) relapse rate.
Database
PubMed
Cochrane Library
CNKI
VIP
CBM
Methods
"Thyroiditis, Subacute" (MeSH) and "Medicine, Chinese Traditional" (MeSH)
"Thyroiditis, Subacute" (in title, abstract, or keywords) and "Medicine, Chinese Traditional" (in title, abstract, or
keywords)
(a): Subacute thyroiditis, giant cell thyroiditis, sub-acute granulomatous thyroiditis and De Quervain thyroiditis
(in titles).
(b): In the result of (a), Traditional Chinese Medicine, Chinese herbal medicine and combination of TCM with
Western Medicine (in full text).
(c): In the result of (b), randomization (in full text).
TCM, or Chinese herbal medicine, or combination of TCM with Western Medicine, and randomization (in full
text), subacute thyroiditis or giant cell thyroiditis or sub-acute granulomatous thyroiditis or De Quervain thyroid-
itis (in title).
TCM or CHM or combination of TCM with Western Medicine, subacute thyroiditis or giant cell thyroiditis or
sub-acute granulomatous thyroiditis or De Quervain thyroiditis and randomization (in full text).
Table 1 Methods for retrieving literature from databases
Notes: CNKI: China National Knowledge Infrastructure Database; VIP: China Science and Technology Journal Database; CBM: China
Biological Medicine Database; TCM: Traditional Chinese Medicine; CHM: Chinese herbal medicine.
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The secondly outcome indexes are: (a) level of erythro-
cyte sedimentation rate (ESR) after treatment, (b) level
of free triiodothyronine (FT3), free thyroxine (FT4),
and thyroid-stimulating hormone (TSH), and (c) safe-
ty index, adverse reactions during trials.
The first three items of the outcome indexes indicate
short-term effectiveness of interventions, while the last
two items indicate long-term effectiveness. The second-
ly outcome indexes are substitutive indexes, or mainly
indexes of laboratory tests. Trials with two of the first
three items of the primary outcome indexes would be
included in the review. Articles with incomplete data
would be excluded because of an inability to analyze
statistically.
Extraction and analysis of data
Extraction of data: researchers extracted data into a ta-
ble. Two researchers extracted and checked data sepa-
rately. The extracted contents include the title of arti-
cles, methodological features, characteristics of partici-
pants (sex, age, illness course, TCM syndrome, amount
of sample, and cases in each group), features of treat-
ment (therapeutic measure, control measure, and treat-
ment course), indexes for evaluating effectiveness, and
adverse reactions.
Evaluation of methodology: the tool provided by the
Cochrane Collaboration for evaluating risk of bias10
was used to assess methodological quality of included
trials in the following six items: generation of random-
ized sequence, concealment of randomized sequence,
practice of blinding method, wholeness of outcome re-
port, result of selective report, and sources of other bi-
as. Two researchers independently carried out assess-
ment and checks. Disputes between them, if any, were
solved through discussion or through submission to a
third researcher.
Statistical analysis of data: RevMan 5.2 software was
used to analyze data extracted from trials. Continuous
variables were expressed with mean difference (MD).
Scattered variables were expressed with relative risk
(RR). 95% confidence interval (CI) was calculated for
two kinds of variables to describe the effect estimate of
treatment. Meta-analysis was carried out for studies
with good homogeneity. Corresponding statistical mod-
els were chosen according to the result of the heteroge-
neity test. Fixed effect models were used for small het-
erogeneity (I2<25% ). Otherwise, randomized effect
models were used.
Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) profiler software pro-
vided by GRADE working team11 was used to evaluate
the quality of evidence in the included trials and explic-
itly recommend grades.
RESULTS
Procedure and result of retrieval
We retrieved 173 articles from five databases. After re-
peatedly retrieved articles were removed, 114 articles
entered the screening process. After abstracts were
screened, 76 articles were preliminarily collected. After
the full texts were read and 55 articles removed, 21
RCTs were finally included.12-32
Basic characteristics of included articles
All 21 RCTs were carried out in China and were writ-
ten in Chinese (19 articles in periodicals and 2 degree
papers) from 2001 to 2012. Sixty three patients were
excluded from the 1360 cases of subacute thyroiditis in
those trials because of no reports on their sex.12,14
Among the remaining 1297 patients, females account-
ed for 79.0% (1024 cases). The sample size range was
35-150, with 65 on average.
Seven trials12,16,18,20,22,25,28 compared CHM with Western
Medicine. Eleven trials13-15,17,19,21,23,24,26,29,31 compared
CHM plus Western Medicine with Western Medicine
alone. Three trials 27,30,32 were divided into three groups
of CHM, CHM plus Western Medicine, and Western
Medicine. CHM treatments included decoction, patent
medicine, externally applied medicines and injections.
Western Medicines included glucocorticoid hormones
(prednisone), NSAIDs, and other treatments used ac-
cording to symptoms. No trials used placebos in the
control group.
Reported outcome indexes of effectiveness included im-
provement of symptoms and signs, blood sedimenta-
tion, thyroid function, incidence of hypothyroidism,
relapse rate, adverse reaction, effective rate, other bio-
chemical indexes, results of pathological tests, results of
imaging tests, and course of treatment.
Details information on the characteristics of trials is
presented in Table 2.
Evaluation of methodological quality
Eighteen articles (85.7%) with no detailed information
on methods of randomized distribution may have risk
of selective bias. Three articles14,19,22 reported methods
of random distribution, namely a random numble ta-
ble,14 random sequence of SAS generation,22 and ran-
domized division of groups, according to the "principle
on minimum distribution of imbalanced indexes",19
with no method for concealing plans on random distri-
bution.
All articles did not report whether blinding was used in
evaluating outcome. Without using placebo or setting
up a blank control, a trial may have a high risk of bias.
One article14 reported no information on three drop-
outs with an unclear risk of dropout bias and the other
articles have a low risk of dropout bias.
Five articles12,20,25,30,31 did not report indexes for assessing
effectiveness have a high risk of selective report. The re-
maining articles with reported results identical to the
research method have a low risk of bias.
All articles failed to report methods for calculating sam-
ple size, statements on relative conflicts of interest, or
whether the clinical trial was registered, which have an
unclear risk of bias (Figure 1).
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Evaluation of effectiveness
All articles are divided into two types according to
their design: CHM vs Western Medicine and CHM
plus Western Medicine vs Western Medicine alone.
Each type is divided into three subgroups further: pred-
nisone subgroup, NSAID subgroup, and prednisone
plus NSAID subgroup. Index data in the articles were
statistically analyzed and their effect values recorded.
Chinese herbal medicine vs Western Medicine
Fever-abating time was reported in nine articles (n=
627): five articles in the prednisone subgroup, two arti-
cles in the NSAID subgroup, and two articles in the
prednisone plus NSAID subgroup. There was no statis-
tical difference (MD: 0.17, 95%CI:﹣0.34 to 0.67; Z=
0.64, P=0.52) between the two groups.
The time for eliminating thyroid pain is reported in
nine articles (n=627): five articles in the prednisone
subgroup, two articles in the NSAID subgroup, and
two articles in the prednisone plus NSAID subgroup.
There was no statistical difference (MD: ﹣0.45, 95%
CI: ﹣1.11 to 0.22; Z=1.32, P=0.19) between the two
groups.
Goiter-subsiding time was reported in nine articles (n=
627): five articles in the prednisone subgroup, two arti-
cles in the NSAID subgroup, and two articles in the
prednisone plus NSAID subgroup. There was a statisti-
cal difference (MD:﹣2.76, 95%CI:﹣5.21 to﹣0.31;
Z=2.55, P=0.01) between the two groups, indicating
that CHM are superior to prednisone, NSAIDs, or
prednisone plus NSAIDs in effectiveness on goiter-sub-
siding time.
The level of blood sedimentation after treatment is re-
ported in seven articles (n=541): three articles in the
prednisone subgroup, two articles in the NSAID sub-
group, and two articles in the prednisone plus NSAID
subgroup. There was no statistical difference (MD:
﹣0.66, 95%CI: ﹣1.42 to 0.10; Z=1.70, P=0.09) be-
tween the two groups.
For thyroid function after treatment, the level of FT3
and FT4 is reported in three articles (n=280) and the
level of TSH in two articles (n=240). There was no sta-
tistical difference (FT3: MD: ﹣0.56, 95%CI: ﹣1.72
to 0.60; Z=0.94, P=0.35; FT4: MD: ﹣1.06, 95%CI:
﹣3.49 to 1.37; Z=0.85, P=0.39; TSH: MD: ﹣0.19,
95%CI: ﹣0.49 to 0.11; Z=1.23, P=0.22) between the
two groups.
The incidence of hypothyroidism is reported in two ar-
ticles (n=210): one article on CHM vs. prednisone and
one article on CHM vs NSAIDs, with no statistical dif-
ference (MD: ﹣0.14, 95%CI: 0.02 to 1.18; Z=1.81,
P=0.07) between the two groups.
Relapse rate was reported in seven articles (n=541):
three articles in the prednisone subgroup, two articles
in the NSAID subgroup, and two articles in the predni-
sone plus NSAID subgroup, with statistical differences
(MD: 0.24, 95%CI: 0.12 to 0.46; Z=4.30, P<0.001)
between the two groups, indicating that CHM are su-Stu
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perior to Western Medicine in the effectiveness on re-
ducing the relapse rate of subacute thyroiditis.
Table 3 shows detailed information on the effect value
and statistical methods in various subgroups.
Chinese herbal medicine plus Western Medicine vs
Western Medicine alone
Fever-abating time was reported in twelve articles (n=
640): nine articles in the prednisone subgroup, two ar-
ticles in the NSAID subgroup, and two articles in the
prednisone plus NSAID subgroup, with statistical dif-
ference (MD: ﹣1.06, 95%CI: ﹣1.57 to ﹣0.56; Z=
4.10, P<0.001) between the two groups, indicating
that CHM plus Western Medicine is superior to West-
ern Medicine alone in fever-abating effect on subacute
thyroiditis.
Time of abating thyroid pain is reported in 14 articles
(n=744): eleven articles in the prednisone subgroup,
two articles in the NSAID subgroup, and one article in
the prednisone plus NSAID subgroup, with statistical
difference (MD:﹣1.40, 95%CI:﹣2.00 to﹣0.80; Z=
4.57, P<0.001) between the two groups, indicating
that CHM plus Western Medicine is superior to West-
ern Medicine alone in analgesic effect on subacute thy-
roiditis.
Goiter-abating time is reported in twelve articles (n=
546): eleven articles in the prednisone subgroup and
one article in the prednisone plus NSAID subgroup,
with statistical difference between the two groups
(MD: ﹣3.93, 95%CI: ﹣5.50 to ﹣2.36; Z=4.92, P<
0.001), indicating that CHM plus Western Medicine
is superior to Western Medicine alone in repercussive
effect on subacute thyroiditis.
The level of blood sedimentation after treatment is re-
ported in five articles (n=266): three articles in the
prednisone subgroup, one article in the NSAID sub-
group, and one article in the prednisone plus NSAID
subgroup, with no statistical difference between the
two groups (MD: ﹣2.44, 95%CI: ﹣5.07 to 0.20; Z=
1.81, P=0.07).
For thyroid function after treatment, the levels of FT3
and FT4 are reported in four articles (n=195) and the
level of TSH in one article (n=52) with no statistical
differences in FT3 (MD: ﹣1.03, 95%CI: ﹣2.56 to
0.49; Z=1.33, P=0.18) and FT4 (MD: ﹣ 1.41, 95%
CI: ﹣3.57 to 0.76; Z=1.27, P=0.20). There was a sta-
tistical difference in TSH (MD: 2.07, 95%CI: 0.88 to
3.26; Z=3.41, P<0.001) between the two groups. No
articles report the incidence of hypothyroidism.
Relapse rate is reported in eleven articles (n=601): nine
articles in the prednisone subgroup, one article in the
NSAID subgroup, and one article in the prednisone
plus NSAID subgroup, with statistical difference be-
tween the two groups (MD: 0.21, 95% CI: 0.13 to
0.33; Z=6.46, P<0.001), indicating that CHM plus
Western Medicine is superior to Western Medicine
alone in reducing relapse rate of subacute thyroiditis.
Table 4 shows detailed information on effect value and
statistical methods in the subgroups.
Evaluation of GRADE evidence
To take RCTs on the treatment of subacute thyroiditis
with CHM vs Western Medicine for example, the data
recorded in RevMan software were put in GRADE pro-
filer software. The software can assess the quality of evi-
dence in the included studies, form grades of evidence,
and recommend their classification. The treatment of
subacute thyroiditis with CHM have a moderate quali-
ty of evidence in shortening time of fever, goiter, and
pain, and reducing blood sedimentation, indicating
that future high-quality research may seriously influ-
ence the present conclusions of these studies. The treat-
ment of subacute thyroiditis with CHM has a poor
quality of evidence in improving thyroid function and
reducing incidence of hypothyroidism and relapse rate
of subacute thyroiditis, indicating that future
high-quality studies may change the present conclu-
sions (Table 5).
Evaluation of safety
Eight articles report information on safety. Six articles
report types and sufferers of adverse reactions.16,19-22,31
One article32 reported that after treatment, the body
weight of patients increased by (3.69±4.14) kg in the
hormone control group and decreased (0.23±1.12) kg
in the CHM combined with Western Medicine control
group, without reporting other adverse reactions and
sufferers. One article30 reported that no obvious adverse
reactions occurred in the treatment group, and gastric
discomfort, acid regurgitation, and polyphagia ap-
peared in some patients of the control group without
reporting sufferers.
Twelve patients in the treatment group and 49 patients
in the control group suffered from adverse reactions
with a statistical difference between the two groups
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
High risk of biasLow risk of bias Unclear risk of bias
Figure 1 Evaluation of methodological quality of RCTs on the treatment of subacute thyroiditis with Chinese herbal medicine
RCT: randomized controlled trial.
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(RR: 0.12, 95%CI: 0.03 to 0.51; Z=2.89; P=0.004).
Adverse reactions included upper-abdominal discom-
fort (22 cases, 36.1%), increase in body weight (8 cas-
es, 13.1%), increase in ALT (5 cases, 8.2%), insomnia
(3 cases, 4.9%), skin rash (3 cases, 4.9%), visual blur-
ring (2 cases, 3.3%), increased blood pressure (2 cases,
3.3% ), and other hormone side-effects (18 cases,
29.5%) (without details).
Table 3 Effect indexes of RCTs on the treatment of subacute thyroiditis with Chinese herbal medicine vsWestern Medicine
Outcome of subgroup
1. Duration of fever
1.1 CHM vs P
1.2 CHM vs P&N
1.3 CHM vs N
2. Duration of thyroid pain
2.1 CHM vs P
2.2 CHM vs P&N
2.3 CHM vs N
3. Duration of goiter
3.1 CHM vs P
3.2 CHM vs P&N
3.3 CHM vs N
4. ESR
4.1 CHM vs P
4.2 CHM vs P&N
4.3 CHM vs N
5. FT3
5.1 CHM vs P
5.2 CHM vs P&N
5.3 CHM vs N
6. FT4
6.1 CHM vs P
6.2 CHM vs P&N
6.3 CHM vs N
7. TSH
7.1 CHM vs P
7.2 CHM vs P&N
7.3 CHM vs N
8. Rate of hypothyroidism
8.1 CHM vs P
8.2 CHM vs P&N
8.3 CHM vs N
9. Relapse rate (>2 months)
9.1 CHM vs P
9.2 CHM vs P&N
9.3 CHM vs N
Study
9
5
2
2
9
5
2
2
9
5
2
2
7
3
2
2
3
1
0
2
3
1
0
2
2
0
0
2
2
1
0
1
7
3
2
2
Participant
627
248
139
240
627
248
139
240
627
248
139
240
541
162
139
240
280
40
0
240
280
40
0
240
240
0
0
240
210
60
0
150
541
162
139
240
Statistical method
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Fixed, 95% CI)
MD (IV, Fixed, 95% CI)
MD (IV, Fixed, 95% CI)
MD (IV, Fixed, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Fixed, 95% CI)
MD (IV, Fixed, 95% CI)
MD (IV, Fixed, 95% CI)
MD (IV, Fixed, 95% CI)
OR (M-H, Fixed, 95% CI)
OR (M-H, Fixed, 95% CI)
OR (M-H, Fixed, 95% CI)
OR (M-H, Fixed, 95% CI)
OR (M-H, Fixed, 95% CI)
OR (M-H, Fixed, 95% CI)
OR (M-H, Fixed, 95% CI)
OR (M-H, Fixed, 95% CI)
Effect estimation
0.17 [-0.34, 0.67]
0.22 [-0.74, 1.19]
0.64 [-2.93, 4.20]
-0.16 [-0.57, 0.25]
-0.45 [-1.11, 0.22]
0.06 [-1.39, 1.50]
0.99 [-4.94, 6.91]
-1.11 [-1.96, -0.26]
-2.76 [-5.21, -0.31]
-2.78 [-6.57, 1.00]
0.21 [-8.54, 8.96]
-5.45 [-7.44, -3.45]
-0.66 [-1.42, 0.10]
-0.28 [-1.98, 1.42]
0.88 [-0.70, 2.47]
-1.41 [-2.41, -0.41]
-0.56 [-1.72, 0.60]
0.49 [-0.74, 1.72]
Not estimable
-1.15 [-1.57, -0.73]
-1.06 [-3.49, 1.37]
1.03 [-1.17, 3.23]
Not estimable
-2.05 [-4.16, 0.05]
-0.19 [-0.49, 0.11]
Not estimable
Not estimable
-0.19 [-0.49, 0.11]
0.14 [0.02, 1.18]
0.19 [0.01, 4.06]
Not estimable
0.10 [0.00, 2.05]
0.24 [0.12, 0.46]
0.08 [0.01, 0.62]
0.26 [0.09, 0.76]
0.33 [0.13, 0.86]
Z
0.64
0.46
0.35
0.75
1.32
0.08
0.33
2.55
2.21
1.44
0.05
5.36
1.70
0.32
1.09
2.75
0.94
0.78
-
5.36
0.85
0.92
-
1.91
1.23
-
-
1.23
1.81
1.07
-
1.50
4.30
2.41
2.47
2.27
P value
0.52
0.65
0.73
0.45
0.19
0.94
0.74
0.01
0.03
0.15
0.96
<0.001
0.09
0.75
0.27
0.006
0.35
0.43
-
<0.001
0.39
0.36
-
0.06
0.22
-
-
0.22
0.07
0.29
-
0.13
<0.001
0.02
0.01
0.02
Notes: CHM: Chinese herbal medicine; MD: mean difference; N: non-steroidal anti-inflammatory drugs (NSAIDs); OR: odds ratio; P:
prednisone; P&N: prednisone plus NSAIDs; RCT: ramdomized controlled trial.
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Table 4 Effect indexes of RCTs on the treatment of subacute thyroiditis with Chinese herbal medicine plus Western Medicine vs
Western Medicine alone
Outcome or subgroup
1. Duration of fever
1.1 CHM+P vs P
1.2 CHM+P&N vs P&N
1.3 CHM+N vs N
2. Duration of thyroid pain
2.1 CHM+P vs P
2.2 CHM+P&N vs P&N
2.3 CHM+N vs N
3. Duration of thyroid
enlargement
3.1 CHM+P vs P
3.2 CHM+P&N vs P&N
3.3 CHM+N vs N
4. ESR
4.1 CHM+P vs P
4.2 CHM+P&N vs P&N
4.3 CHM+N vs N
5. FT3
5.1 CHM+P vs P
5.2 CHM+P&N vs P&N
5.3 CHM+N vs N
6. FT4
6.1 CHM+P vs P
6.2 CHM+P&N vs P&N
6.3 CHM+N vs N
7. TSH
7.1 CHM+P vs P
7.2 CHM+P&N vs P&N
7.3 CHM+N vs N
8. Rate of hypothyroidism
9. Relapse rate (>2 months)
9.1 CHM+P vs P
9.2 CHM+P&N vs P&N
9.3 CHM+N vs N
Study
12
9
1
2
14
11
1
2
11
10
1
0
5
3
1
1
4
3
0
1
4
3
0
1
1
0
0
1
0
11
9
1
1
Participant
640
458
71
111
744
562
71
111
546
475
71
0
266
143
71
52
195
143
0
52
195
143
0
52
52
0
0
52
0
601
471
71
59
Statistical method
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
MD (IV, Random, 95% CI)
OR (M-H, Fixed, 95% CI)
OR (M-H, Fixed, 95% CI)
OR (M-H, Fixed, 95% CI)
OR (M-H, Fixed, 95% CI)
OR (M-H, Fixed, 95% CI)
Effect estimate
-1.06 [-1.57, -0.56]
-1.25 [-1.84, -0.66]
-0.12 [-0.42, 0.18]
-0.72 [-1.39, -0.04]
-1.40 [-2.00, -0.80]
-1.14 [-1.77, -0.50]
-0.41 [-1.22, 0.40]
-3.68 [-6.77, -0.60]
-3.93 [-5.50, -2.36]
-4.18 [-5.82, -2.55]
-1.63 [-4.00, 0.74]
Not estimable
-2.44 [-5.07, 0.20]
-3.24 [-8.94, 2.47]
-0.56 [-2.45, 1.33]
-3.27 [-4.49, -2.05]
-1.03 [-2.56, 0.49]
-0.25 [-0.97, 0.47]
Not estimable
-3.27 [-4.49, -2.05]
-1.41 [-3.57, 0.76]
-0.33 [-1.77, 1.10]
Not estimable
-5.00 [-7.96, -2.04]
2.07 [0.88, 3.26]
Not estimable
Not estimable
2.07 [0.88, 3.26]
Not estimable
0.21 [0.13, 0.33]
0.21 [0.13, 0.36]
0.10 [0.01, 0.87]
0.25 [0.06, 1.03]
Z
4.10
4.14
0.77
2.09
4.57
3.51
0.99
2.34
4.92
5.01
1.35
-
1.81
1.11
0.58
5.26
1.33
0.67
-
5.26
1.27
0.46
-
3.32
3.41
-
-
3.41
-
6.46
5.77
2.09
1.92
P value
<0.001
<0.001
0.44
0.04
<0.001
<0.001
0.32
0.02
<0.001
<0.001
0.18
-
0.07
0.27
0.56
<0.001
0.18
0.50
-
<0.001
0.20
0.65
-
<0.001
<0.001
-
-
<0.001
-
<0.001
<0.001
0.04
0.06
Notes: CHM: Chinese herbal medicine; MD: mean difference; N: non-steroidal anti-inflammatory drugs (NSAIDs); OR: odds ratio; P:
prednisone; P&N: prednisone plus NSAIDs. ESR: erythrocyte sedimentation tate; FT3: free triiodothyronine; FT4: free thyroxine ; TSH:
thyroid-stimulating hormone; RCT: randomized controlled trials.
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DISCUSSION
This article has systematically summarized articles on
RCTs on the treatment of subacute thyroiditis with
CHM or CHM plus Western Medicine. We found
that CHM may be similar to Western Medicine (pred-
nisone and NSAIDs) in abating fever, alleviating thy-
roid pain, restoring blood sedimentation, improving
thyroid function, and preventing hypothyroidism, and
may be superior to Western Medicine in subsiding goi-
ters and reducing relapse rate. CHM plus Western
Medicine may be superior to Western Medicine in abat-
ing fever, alleviating thyroid pain, subsiding goiter, and
reducing relapse rate, and may be similar to Western
Medicine in restoring blood sedimentation and improv-
ing thyroid function. Because of a lack of research, the
effectiveness of CHM plus Western Medicine is un-
clear for preventing hypothyroidism. The incidence of
adverse reactions caused by CHM or CHM plus West-
ern Medicine may be lower than that caused by West-
ern Medicine alone.
Using the Cochrane Collaboration's tool for evaluating
risk of bias and the methods for classifying GRADE ev-
idence in the Cochrane handbook, we have discovered
a poor quality of current evidence in RCTs on using
CHM to treat subacute thyroiditis. Some bias may ex-
ist in the results of these trials because most trials re-
port no methods of randomized distribution and con-
cealment of distribution method. Additionally, none of
the trials use blinding methods or include methods for
calculating sample sizes. No exact conclusions on the
effectiveness of treating subacute thyroiditis with
CHM can be drawn from this systematic review. Part
of the conclusions drawn from this systematic review
may be changed in case of higher quality RCTs being
conducted in the future.
Outcome
Mean duration of fever
Mean duration of thyroid
pain
Mean duration of thyroid
enlargement
Mean ESR
Mean FT3
Mean FT4
Mean TSH
Rate of
hypothy
roidism
Relapse
rate
Study population
Moderate
Study population
Moderate
Conventional
treatment
3.46 days
4.62 days
19.2 days
12.9 mm/h
8.2 pmol/L
15.9 pmol/L
3.3 μg/L
50 per 1000
53 per 1000
155 per 1000
140 per 1000
Chinese herbal medicine
0.17 lower (0.34 to
0.67 higher)
0.45 lower (1.11 lower
to 0.22 higher)
2.76 lower (5.21 to
0.31 lower)
0.66 lower (1.42 lower
to 0.1 higher)
0.56 lower (1.72 lower
to 0.6 higher)
1.06 lower (3.49 lower
to 1.37 higher)
0.19 lower (0.49 lower
to 0.11 higher)
7 per 1000 (1 to 58)
8 per 1000 (1 to 62)
42 per 1000 (21 to 78)
38 per 1000 (19 to 70)
Relative
effect
(95% CI)
-
-
-
-
-
-
-
OR 0.14
(0.02 to
1.18)
OR 0.24
(0.12 to
0.46)
No. of partici-
pants
(studies)
627
(9 studies)
627
(9 studies)
627
(9 studies)
541
(7 studies)
280
(3 studies)
280
(3 studies)
240
(2 studies)
210
(2 studies)
541
(7 studies)
Quality of the evi-
dence
(GRADE)
moderate1,2
moderate1,2,3
moderate1,2,3,4
moderate1,2
low2,3,5
low2,5,6
low2
low2,4,6
low1,3
Table 5 Evaluation of GRADE evidence in RCTs on the treatment of subacute thyroiditis with Chinese herbal medicine vsWestern
Medicine
Notes: GRADE Working Group grades of evidence: high quality: further research is very unlikely to change our confidence in the esti-
mate of effect. Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may
change the estimate. Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect
and is likely to change the estimate. Very low quality: we are very uncertain about the estimate. CI: confidence interval; OR: odds ratio;
ESR: erythrocyte sedimentation rate; FT3: free triiodothyronine; FT4: free thyroxine; TSH: thyroid-stimulating hormone; GRADE: grad-
ing of recommendations assessment, development and evaluation; RCT: randomized controlled trials. Evaluation of GRADE evidence:
1randomization is not reported sufficiently; 2blinding was not used in the process of trial and outcome assessment; 3funnel plot is asymmet-
rical; 4the effect was large (MD or RR >2 or <1); 5indirect evidence; 6serious imprecision.
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Dosage form, medication, and recipe of CHM used in
the 21 trials included in this article differ greatly. Al-
though obvious heterogeneity of treatment embodies
TCM characteristics, it makes this study unable to rec-
ommend any specific CHM to treat subacute thyroid-
itis.
This article is limited in the following respects. Some
articles only reported the compound index "effective
rate", while identical standards of its evaluation were
excluded, making us unable to cover all the clinical evi-
dence of using CHM to treat subacute thyroiditis. Ad-
ditionally, the effectiveness of CHM was compared
with that of Western Medicine and each group was di-
vided into subgroups to carry out Meta-analysis. There-
fore, we can only generally analyze the tendency on ef-
fectiveness of CHM and but not evaluate the effective-
ness of individual CHM. This restricts any deductions
we can make.
Despite the poor quality of included trials in this
study, we found from summarizing the evidence that
CHM (especially CHM plus Western Medicine) used
to treat subacute thyroiditis can improve clinical symp-
toms and signs, reduce relapse rate, and alleviate the
side effects of hormones. These conclusion need to be
confirmed by future high quality research.
We suggested considering the following points in fu-
ture research: (a) the conducting and reporting of
RCTs should abide by international standards, especial-
ly in the methods for generating randomized sequence
and concealing distribution plans. (b) In research on
Chinese patent medicine, CHM plus western placebo
vs Western Medicine plus Chinese placebo can be used.
In research into Chinese decoctions and external treat-
ments, pragmatic randomized open controlled trials
should be used. (c) Dropouts during researches should
be reported in detail. Methods for intentionally analyz-
ing data must be used. (d) In evaluating effectiveness,
measurable terminal indexes, substitutive indexes, and
symptoms and signs that embody specificity of a dis-
ease should be used, such as symptom-alleviating time,
blood sedimentation, thyroid hormone, relapse rate,
and incidence of hypothyroidism. Confidence intervals
and P-values should be reported.33 Researchers should
also avoid using compound indexes (derived from com-
prehensively considering clinical symptoms, signs, bio-
chemical examination, and imaging test). (e) Informa-
tion on safety during research should be reported in de-
tail. (f ) If permitted, the registration of clinical trials
should be considered beforehand.
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